CKJ REVIEW

Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics

Nuria Montero, Laia Oliveras, Maria José Soler and Josep Maria Cruzado

Department of Nephrology, L’Hospitalet de Llobregat, Hospital Universitari de Bellvitge, Barcelona, Spain,
Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, University of Barcelona, Barcelona, Spain
and Department of Nephrology, Hospital Vall d’Hebron, Barcelona, Spain

Correspondence to: Nuria Montero; E-mail: nuriamonteroperez@gmail.com

ABSTRACT

Post-transplant diabetes mellitus (PTDM) is a common problem after kidney transplantation (KT), occurring in 50% of high-risk recipients. The clinical importance of PTDM lies in its impact as a significant risk factor for cardiovascular and chronic kidney disease (CKD) after solid organ transplantation. Kidney Disease: Improving Global Outcomes (KDIGO) has recently updated the treatment guidelines for diabetes management in CKD with emphasis on the newer antidiabetic agents such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium–glucose co-transporter 2 inhibitors as add-on therapy to metformin. Given all these new diabetes treatments and the updated KDIGO guidelines, it is necessary to evaluate and give guidance on their use for DM management in KT recipients. This review summarizes the scarce published literature about the use of these new agents in the KT field. In summary, it is absolutely necessary to generate evidence in order to be able to safely use these new treatments in the KT population to improve blood glucose control, but specially to evaluate their potential cardiovascular and renal benefits that would seem to be independent of blood glucose control in PTDM patients.

Keywords: diabetes mellitus, dipeptidyl peptidase-4 inhibitors, incretins, kidney transplantation, sodium–glucose co-transporter 2 inhibitors

INTRODUCTION

Post-transplant diabetes mellitus (PTDM) is a common problem after kidney transplantation (KT) [1], occurring in 50% of high-risk recipients. The nomenclature of this disease changed after 2013; previously it was called new onset diabetes after transplantation (NODAT), but this term changed because it implied the exclusion of diabetes mellitus (DM) pre-transplantation, a problem that can potentially be unrecognized [2]. Currently, between preexisting DM and PTDM, approximately 50% of KT recipients require diabetic management [3].

Pre-transplant risk factors such as age, obesity, male gender, genetic background and hypertriglyceridaemia increase the risk of PTDM up to 50% [4]. In combination with some peritransplant triggers like immunosuppression, surgery stress, hypomagnesaemia and viral infections promote glucose intolerance and PTDM [5]. The pathophysiology of PTDM is related to β-cell damage; dysfunctional insulin release; impaired insulin-mediated glucose uptake in the peripheral tissue; impaired insulin-mediated suppression of hepatic glucose output secondary to disability of the incretin axis between the...
gut and pancreas; and impairment of brain regulation of the appetite, white fat mass and hepatic glucose output [1] (Figure 1).

The clinical importance of PTDM lies in its unquestionable impact as a significant risk factor for cardiovascular disease (CVD) and chronic kidney disease (CKD) in solid organ transplantation [6]. Diabetic nephropathy is a major cause of CKD in liver transplants [7]. Also, diabetic nephropathy is found early after KT in patients with PTDM and is associated with kidney allograft failure [8]. The development of PTDM is a costly condition, with 67% increased risk of graft failure and an 87% increased risk of death due to premature CVD, cardiovascular deaths and infections [9]. Worse results are seen in those recipients with previous DM [10].

Kidney Disease: Improving Global Outcomes (KDIGO) has recently updated the treatment guidelines for diabetes management in CKD with emphasis on the newer antidiabetic agents such as dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium–glucose co-transporter 2 inhibitors (SGLT2i) as add-on therapy to metformin [11]. Some of these new agents show nephroprotective effects that are beyond glycaemic control.

In the early post-transplantation period, the most usual treatment is based on insulin analogues. This is usually challenging, since conditions change rapidly [changes in renal function, nutrition management, gastrointestinal (GI) motility disturbances or adjustment of immunosuppressive drugs]. In these recipients, it required intensive blood glucose monitoring and flexible and safe treatment algorithms. Oral drugs such as metformin are generally not used in transplant recipients due to their reduced renal function and the increased risk for metabolic acidosis.

Given all these interesting factors and the potential renoprotective effect of these agents, the appearance of new diabetes treatments and the updated KDIGO guidelines, it is necessary to evaluate and give guidance on DM management in KT recipients.

**INCRETIN AGENTS**

In this classification, we include GLP-1 RA and the DPP-4i. They stimulate β-cell function, slow gastric emptying and decrease insulin resistance [12]. GLP-1 RAs also suppress appetite. The use of them is associated with low risk of hypoglycaemia because of their glucose-dependent stimulation of insulin secretion [13].

Currently, there are six European Medicines Agency (EMA) approved GLP-1 RAs agents: exenatide, liraglutide, lixisenatide, albiglutide, semaglutide and dulaglutide, and five EMA-approved DPP-4i: sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin [14].

**Glucagon-like peptide-1 receptor agonists**

There are two main molecules that control insulin secretion by β-cells following nutrient ingestion: glucose-dependent insulinotrophic polypeptide (GIP) and GLP-1 RA [15]. GLP-1 RA are structurally similar to endogenous GLP-1 released from gut enteroendocrine cells but have been engineered to be resistant to DPP-4 degradation [15]. GLP-1 RA exert their main effect by inhibiting inappropriate post-meal glucagon secretion and by suppressing hepatic glucose production, but they also delay gastric emptying and suppress central appetite. Compared with DPP-4i, haemoglobin A1c (HbA1c) reduction is higher, reported to be from 1% to 1.5% [16].

In case of type 2 DM, GLP-1 RA are preferred if there is a need to promote weight loss or also in patients with established CVD or heart failure [13].

Some selected published studies with GLP-1 RA use in KT are presented in Table 1.

In case of PTDM, GLP-1 RAs have the following potential benefits:

i. Metabolic impact: increases insulin secretion and reduces glucagon secretion. This effect has been shown in the Halden et al. [18] study, which compared 12 KT recipients with PTDM and 12 without. Infusions of GLP-1 were compared with saline infusions, establishing a hyperglycaemic clamp. The authors characterized PTDM by a reduced glucose-induced insulin secretion and attenuated glucagon suppression with improvement of both defects by GLP-1 infusion (reduction in glucagon levels in GLP-1 group: −22 ± 15%; P = 0.007, and improved maximal insulin stimulation by 102%; P = 0.003). Published studies in PTDM recipients show a similar effect on glucose control using GLP1-AR compared with the general type 2 DM population. For example, in a brief case series including seven KT recipients with PTDM, the addition of liraglutide to other antidiabetic agents entailed a significant reduction of HbA1c from 10.04% to 8.14% (P = 0.047) [19]. This beneficial effect on glucose control is similar between the different molecules, but reductions on daily insulin requirements are more pronounced using dulaglutide compared with liraglutide (−26% versus −3.6%; P = 0.01) in the solid organ transplant population, which may be related to dulaglutide’s longer duration of action [21].
In the general type 2 DM population, there are differences in efficacy in terms of weight loss depending on the GLP-1 RA agent. Although there are few randomized controlled trials (RCTs) that directly compare the relative efficacy of drugs in weight loss, the available head-to-head comparisons (semaglutide versus exenatide extended release/dulaglutide/liraglutide; exenatide immediate release versus dulaglutide and dulaglutide versus exenatide/albiglutide), it has been shown that semaglutide is the most potent molecule in terms of weight reduction in comparison with the rest of the GLP-1 RA [22, 23]. Results in studies including KT recipients only evaluated differences between dulaglutide versus liraglutide and they also confirmed this reduction of weight at 24 months with liraglutide use [21].

Cardiovascular effects: reducing cardiovascular events. A benefit in terms of reducing cardiovascular events has been shown in most of the published studies in the type 2 DM population [24–27]. In the KT population, only two retrospective studies reported the number of cardiovascular events, but without being able to reach any conclusion [20, 21].

Kidney effects: increase of renoprotection. These effects have been largely demonstrated in type 2 DM trials [24, 26]. In this population, in terms of kidney function improvements, the use of GLP-1 RAs reduced the urine albumin-to-creatinine ratio and slowed estimated glomerular filtration rate (eGFR) decline [24, 25, 28, 29]. In KT, results have not been so overwhelming and with differences depending on the GLP-1 RA agent. In a retrospective study including 63 patients, the use of dulaglutide resulted in no significant changes in eGFR after 24 months (in 13 patients: +6.54 mL/min/1.73 m²; P = 0.07) [20]. These results were not confirmed in another cohort of 25 PTDM recipients treated with liraglutide, the authors justified this discrepancy because of a potential increase of glomerular hyperfiltration in obese recipients [21].

Adverse effects related to GLP-1 RA use are headaches, injection site pain and, importantly in KT recipients, mild GI intolerances (nausea and reduced appetite) that can potentially be worsened by concomitant use of mycophenolate [19]. Because these GI side effects are mediated by different mechanisms—in GLP-1 RA by suppression of central appetite and delay of gastric emptying and in mycophenolate by the inhibition of the replication of GI epithelial cells, leading to disruption of fluid absorption and diarrhoea—they can be potentiated by the concurrent use of the two types of drugs.

There are no interactions with immunosuppressants mediated by CYP (cytochrome P450 enzymes) or transporters [30] (Supplementary data, Table S1) [31–33]. Some observational studies showed that delays in gastric emptying related to GLP-1 RAs did not alter levels or doses of immunosuppression [19].

Each GLP-1 RA agent has different posology: exenatide twice a day (should be administered within 60 min before main

### Table 1. Published studies with GLP-1 RA use in KT

<table>
<thead>
<tr>
<th>Study id</th>
<th>Study design, follow-up</th>
<th>Population</th>
<th>Intervention/s</th>
<th>Outcome</th>
</tr>
</thead>
</table>
| Pinelli et al. [17] | • Case series, n = 5  
• Follow-up: 3 weeks | KT recipients with or without previous DM or PTDM, with stable renal function receiving tacrolimus | All patients received liraglutide in monotherapy | • Reduction of postprandial blood glucose levels at 60 (7.3 ± 1.2 versus 5.9 ± 0.5 mmol/L) and 120 min (7.1 ± 0.8 versus 6.0 ± 0.4 mmol/L); no decrease of FBS  
• Reduction in insulin units with dulaglutide  
• Significant weight decrease with dulaglutide or liraglutide  
• Reduction of HbA1c from 10.0 to 7.6% (P < 0.001) |
| Halden et al. [18] | • RCT, n = 24 (PTDM n = 12, without PTDM n = 12) | KT with and without PTDM | Intra venous infusion of GLP-1 versus saline (placebo) | • GLP-1 improves glucose-induced insulin secretion and glucagon suppression in PTDM patients  
• Decrease of FBS from 228.6 ± 39.1 to 166.0 ± 26.6 mg/dL (P = 0.103)  
• Reduction of HbA1c from 10.0 ± 1.6% to 8.1 ± 0.8% (P = 0.017)  
• Weight loss from 78.0 ± 7.8 to 77.7 ± 12.3 kg (P = 0.922) |
| Liou et al. [19] | • Retrospective case series, n = 7  
• Mean follow-up: 19.4 ± 7.6 months | KT recipients with PTDM treated with liraglutide | All patients received liraglutide | • Reduction of FBS, 6.5 ± 1.6 mmol/L  
• Weight loss of 7.1 kg (P < 0.0001)  
• Reduction of HbA1c from 8.3 ± 0.7% to 7.6 ± 0.7% (P < 0.003)  
• No statistical differences between groups in HbA1c changes |
| Singh et al. [20] | • Retrospective case series, n = 63  
• Follow-up: 24 months | SOT recipients with DM using dulaglutide  
*Includes both type-2 DM (43 patients) and PTDM (20 patients) | All patients received dulaglutide | • Statistically significant weight reduction: mean paired difference at 6, 12 and 24 months of 2.07 (P < 0.003), 4.007 (P < 0.001) and 5.23 (P < 0.034) kg  
• Insulin reduction: mean paired difference of 5.94 units (P < 0.0002) |
| Singh et al. [21] | • Retrospective cohort, n = 88 (dulaglutide n = 63, liraglutide n = 25)  
• Follow-up: 24 months | SOT patients with DM treated with dulaglutide or liraglutide  
*Includes both type-2 DM (43 patients) and PTDM (20 patients) | All patients received dulaglutide or liraglutide | • Significant weight decrease with dulaglutide compared with liraglutide (2% versus 0.09%; P = 0.003)  
• Reduction in insulin units with dulaglutide compared with liraglutide (26% versus 3.6%; P = 0.01)  
• No statistical differences between groups in HbA1c changes |

FBS, fasting blood sugar; SOT, solid organ transplant.
meals); liraglutide once daily (QD) (at any time, without regard to meals); lixisenatide QD (should be administered within 60 min before main meals); or exenatide, albglutide, semaglutide and dulaglutide each given once weekly [14]. GLP-1 RAs are cleared by proteolytic degradation and glomerular filtration, so dose adjustments depending on kidney function are required with exenatide and lixisenatide.

**Dipeptidyl peptidase-4 inhibitors**

DPP-4i act indirectly by blocking proteolytic cleavage of GLP-1 by DPP-4 [34]. This generates a glucose-lowering effect, but apart from that, it also promotes β-cell proliferation, neogenesis and inhibition of apoptosis [35].

Some selected published studies with DPP-4i use in KT are presented in Table 2.

In the case of PTDM, DPP-4i have these potential roles:

1. **Metabolic impact:**
   a. Repairing pathophysiologic aetiologies of insulin resistance and β-cell dysfunction: there are two published studies that show an improvement of insulin resistance with DPP-4i treatment in the early KT. Thiruvengadam et al. [34] compared the use of lixisinap (n = 19) versus other therapies (metformin, insulin or sulphonylureas) (n = 21) after the early diagnosis of PTDM, showing an improvement of insulin resistance [evaluated by the calculated homeostatic model assessment for insulin resistance (HOMA-IR) scores (2.21 versus 3.33; P = 0.02)]. This effect was also shown in the Strøm Halden study [41], including 19 patients who were randomly assigned to be treated for 4 weeks with sitagliptin just after the diagnosis of diabetes followed by 4 weeks of no treatment or vice versa. The authors described an increased insulin secretion response and an increased insulin sensitivity with sitagliptin (median sensitivity increase of 25.3%; P = 0.04).
   b. Use as adjunctive therapy: lowering insulin requirements early post-transplantation. One of the main pathologic pathways of PTDM appearance is because of impaired insulin secretion. As opposed to sulphonylureas, DPP-4i improve insulin response without aggravating β-cell decline via islet cell exhaustion. This has been shown in some cohort studies by a significant increase in C-peptide values corrected for creatinine and glucose indicating that DPP-4i improved β-cell function in KT recipients [41] but also in type 2 DM patients. In another study, the authors showed lower requirements of insulin doses with combined linagliptin use than insulin alone (24.2 versus 37.5 daily units of insulin; P < 0.05) [42]. All these mechanisms lead to a better control of PTDM, achieving a maintained reduction of HbA1c [36, 39, 40] and an improvement of 2-h plasma glucose (2HPG) on oral glucose tolerance test [37, 40].
   c. Reducing obesity: obesity is related to worse graft and patient outcomes in the short and long term after transplantation [43]. One of the potential effects of long-term treatment with DPP-4i is body mass index reduction, which has been shown in one case series study evaluating the use of sitagliptin in a cohort of 22 recipients, after 12 months of treatment (−0.8 kg/m²; P < 0.05) [39].

2. **Cardiovascular effects:** in the general population, studies using these agents did not show any impact on major adverse cardiovascular events including myocardial infarction, stroke and cardiovascular death [44-47]. In KT, there are no available studies evaluating this outcome.

3. **Kidney effects:** in the general type 2 diabetic population, there have been shown a reduction of albuminuria with the use of saxagliptin [44] and linagliptin [48] without data reported about effects on renal function. In KT population, no information has been reported of the effects of these molecules on albuminuria, but four articles reported no differences in kidney function [36, 37, 39, 44].

Few adverse effects have been described with the use of DPP-4i, with GI intolerances rarely reported.

There are five EMA-approved DPP-4i (sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin), with individual pharmacokinetics (PK) characteristics. There are few known drug interactions with immunosuppressants. However, in the case of KT, initiation of these compounds may require closer monitoring of immunosuppression levels [49]. Depending on the molecule, they can be a P-glycoprotein (PGP) substrate and/or CYP3A4/5 substrate, increasing the likelihood for drug interactions with immunosuppressants [49]. Currently, there are no studies designed specifically to evaluate this potential interaction (Supplementary data, Table S2) [49, 50]. The PK differ depending on the drug concerned: half-life, binding to plasma proteins, the presence of active versus inactive metabolites, predominant renal versus hepatic excretion (necessity of dosage adjustment in case of renal or liver impairment) and propensity for drug–drug interactions [51]. The PK of DPP-4i have been studied in healthy young male subjects, patients with type 2 DM and patients with either renal insufficiency or hepatic impairment [51]. Doses adjustments depending on eGFR are required for sitagliptin, saxagliptin and alogliptin with a reduction of the dose from eGFR <45 mL/min/1.73 m².

**SODIUM–GLUCOSE CO-TRANSPORTER 2 INHIBITORS**

The benefits related to SGLT2i use in terms of kidney function have been widely reported in type 2 DM. Five relevant clinical trials in general type 2 diabetic population (EMPA-REG [52], CANVAS [53], DECLARE [54, 55], CREDENCE [56] and DAPA-CKD [57]) have shown that treatment with SGLT2i is capable of slowing the progression of CKD and the appearance of renal events. The mechanism of action is by increasing urine glucose excretion [58] by inhibiting a low-affinity transport system called SGLT2 that leads renal glucose reabsorption in the proximal tubule of the kidneys. This inhibition of glucose absorption has two benefits: it improves glycaemia control and it also reduces obesity by enhancing glucose and energy loss through the urine by a non-insulin-dependent mechanism of action and these effects improve kidney and cardiovascular outcomes.

Some selected published studies with SGLT2i use in KT are presented in Table 3.

In case of PTDM, SGLT2i have these potential roles:

1. **Metabolic impact:** reducing obesity. Based on small trials, the effect of SGLT2i on lowering HbA1c in KT recipients is modest and it depends on kidney function, but the beneficial effect on renal function appears to be independent of glycaemic control and could be seen in eGFR >20 mL/min/1.73 m². The improvement of metabolic control of PTDM is seen when SGLT2i is added to other antidiabetic medications. In the KT population using empagliflozin compared with placebo, a significant weight loss of −1.6 kg after 4 weeks (P = 0.02), −5 kg at 12 weeks [60] and −2.5 kg (P = 0.014) after 12 months [62] has been shown.
Table 2. Published studies with DPP-4i use in KT

<table>
<thead>
<tr>
<th>Study id</th>
<th>Study design, follow-up</th>
<th>Population</th>
<th>Intervention/s</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lane et al. [36]</td>
<td>• Case series, n = 15</td>
<td>KT recipients with eGFR &gt;30 mL/min/1.73 m² and diagnosis of PTDM</td>
<td>All patients treated with sitagliptin</td>
<td>• Reduction in HbA1c from 7.2 ± 0.1% to 6.7 ± 0.2% (P = 0.002)</td>
</tr>
<tr>
<td></td>
<td>• Follow-up: 3 months</td>
<td></td>
<td></td>
<td>• No patient discontinuation because of side effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• No symptomatic hypoglycaemia</td>
</tr>
<tr>
<td>Sanyal et al. [37]</td>
<td>• Case series, n = 21</td>
<td>KT recipients with diagnosis of PTDM and stable renal function</td>
<td>All patients received lina-glipitin monotherapy (5 mg/day)</td>
<td>• Decrease in FPG of 22.21 mg/dL and decrease in postprandial plasma glucose of 40.07 mg/dL (P &lt; 0.01)</td>
</tr>
<tr>
<td></td>
<td>• Follow-up: 6 months</td>
<td></td>
<td></td>
<td>• Decrease of HbA1c 0.6% in 24 weeks</td>
</tr>
<tr>
<td>Soliman et al. [38]</td>
<td>RCT, n = 62</td>
<td>KT recipients with PTDM receiving metformin and inadequate glycaemic control</td>
<td>Metformin + sitagliptin versus metformin + insulin Rescue therapy: pioglitazone</td>
<td>• Similar reduction in HbA1c in both groups (−0.6 ± 0.5% with sitagliptin and −0.6 ± 0.6% in insulin group)</td>
</tr>
<tr>
<td></td>
<td>• Follow-up: 3 months</td>
<td></td>
<td></td>
<td>• Small weight loss in sitagliptin group (−0.4 kg) and weight gain in insulin group (+0.8 kg); P &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• No severe adverse events</td>
</tr>
<tr>
<td>Boerner et al. [39]</td>
<td>Case series, n = 22</td>
<td>KT recipients with diagnosis of PTDM treated with sitagliptin alone</td>
<td>All patients treated with sitagliptin monotherapy</td>
<td>• Mean HbA1c 6.5 ± 0.5%.</td>
</tr>
<tr>
<td></td>
<td>• Mean follow-up: 32.5 ± 17.8 months</td>
<td></td>
<td></td>
<td>• No episodes of pancreatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Rare transplant-specific adverse events</td>
</tr>
<tr>
<td>Haidinger et al.  [40]</td>
<td>Phase II RCT, n = 33</td>
<td>KT recipients (&gt;6 months post-KT) with stable renal function and diagnosis of PTDM</td>
<td>Vildaglipitin 50 mg/day versus placebo during 3 months</td>
<td>• Reduced HbA1c (6.1% versus 6.5%, P &lt; 0.05) and 2HGP (182.7 versus 231.2 mg/dL, P &lt; 0.05) in the vildaglipitin group versus placebo</td>
</tr>
<tr>
<td></td>
<td>• Follow-up: 4 months</td>
<td></td>
<td></td>
<td>• Mild adverse events, similar rates in both groups</td>
</tr>
<tr>
<td>Strøm Halden et al. [41]</td>
<td>RCT cross-over, n = 19</td>
<td>KT recipients (&gt;1a) with PTDM and stable renal function</td>
<td>4 weeks with sitagliptin followed by 4 weeks with no sitagliptin, versus vice versa * Also includes patients with other oral antidiabetic treatment, maintained with same dose</td>
<td>• Significant increase of insulin secretion with sitagliptin</td>
</tr>
<tr>
<td></td>
<td>• Follow-up: 8 weeks</td>
<td></td>
<td></td>
<td>• Decrease in FPG [0.9 (0.5–1.7) mmol/L; P = 0.003] and 2HGP [2.9 (0.5–6.4) mmol/L; P = 0.004]</td>
</tr>
<tr>
<td>Guardado-Mendoza et al. [42]</td>
<td>Prospective cohort study, n = 28</td>
<td>KT recipients with fasting hyperglicaemia during the first 24 h post-surgery</td>
<td>Linagliptin 5 mg/days plus insulin versus insulin alone</td>
<td>• Lower glucose levels (131.0 ± 15.1 versus 191.1 ± 22.5 mg/dL) and insulin doses (37.5 ± 6.3 versus 24.2 ± 6.6) in the linagliptin + insulin group (P &lt; 0.05)</td>
</tr>
<tr>
<td></td>
<td>• Follow-up: 12 months</td>
<td></td>
<td></td>
<td>• Less severe hypoglicaeina in linagliptin + insulin group (65.1 ± 2.2 versus 54.2 ± 3.3 mg/dL; P = 0.036)</td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose.

Cardiovascular effects: improving cardiovascular outcomes after KT. There are two studies in type 2 diabetic population that proved their ability to lower systolic blood pressure and reduce cardiovascular deaths and heart failure hospitalizations [52, 54]. In a cohort of 7020 patients, the EMPA-REG RCT [52], having poor control of blood pressure levels (>160/100 mmHg) was an exclusion criteria. Most of the included population used renin–angiotensin–aldosterone system (RAAS) blockers before starting the trial and, without specifying if changes of antihypertensive treatment were done, a blood pressure reduction of −3 mmHg was shown with SGLT2i use at the end of the study. In the other RCT including 17 160 patients, the DECLARE-TIMI 58 [54, 55], the authors described similar levels of basal blood pressure with the same percentage of RAAS blockers, beta-blocker or diuretics use, and a significant decrease of systolic blood pressure of 2.7 mmHg and diastolic blood pressure of 0.7 mmHg was seen in the SGLT2i group. In the KT population, this effect of lowering blood pressure was showed only in one observational case-series study with 10 KT recipients treated with empagliflozin, which found a significant reduction of −8 mmHg in systolic blood pressure (P < 0.05), but also the number of antihypertensive was increased from 3 to 4 [60], whereas two other case series of 10 KT each one using canagliflozin [59] and empagliflozin [63], where the authors specified that antihypertensive therapy could be modified by the treating physician if necessary, they found no effect. An RCT including 40 KT recipients randomized to
Table 3. Published studies with SGLT2i use in KT

<table>
<thead>
<tr>
<th>Study id</th>
<th>Study design, follow-up</th>
<th>Population</th>
<th>Intervention/s</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajasekaran et al. [59]</td>
<td>• Case series, n = 11&lt;br&gt;• Follow-up: 80.5 person-months after canaglifozin initiation</td>
<td>KT (n = 6) and SPKT (n = 4) recipients treated with canaglifozin</td>
<td>All patients treated with canaglifozin</td>
<td>• No urinary nor mycotic infections.&lt;br&gt;• No major complications&lt;br&gt;• Small reductions in eGFR (−4.3 ± 12.2 mL/min/1.73 m²; P = 0.3), but no episodes of AKI&lt;br&gt;• Discrete HbA1c reduction of −0.84 ± 1.2% (P = 0.07)</td>
</tr>
<tr>
<td>Schwaiger et al. [60]</td>
<td>• Prospective interventional study, n = 14&lt;br&gt;• Follow-up: 4 weeks (n = 14), 12 months (n = 8)</td>
<td>KT with PTDM receiving treatment with insulin and eGFR &gt;30 mL/min/1.73 m²</td>
<td>Four weeks on stable insulin treatment, and after a 3-day insulin wash-out, conversion to empaglifozin in monotherapy. Reinstitution of insulin if poor glycaemic control&lt;br&gt;• Concomitant antidiabetic drugs were discontinued</td>
<td>• Increased FPG from 111 ± 21 to 144 ± 45 mg/dL (P = 0.005) and 2HGP from 232 ± 82 to 273 ± 116 mg/dL (P = 0.06) in 4 weeks&lt;br&gt;• Decrease of body weight from 83.7 ± 7.6 to 81.6 ± 7.4 kg in 4 weeks (P = 0.03) and to 78.7 kg in 12 months (P = 0.02)&lt;br&gt;• Decrease of eGFR from 55.6 ± 20.3 to 47.5 ± 15.1 mL/min/1.73 m² (P = 0.008). Not statistically significant differences in 12 months</td>
</tr>
<tr>
<td>Attallah et al. [61]</td>
<td>• Case series, n = 8&lt;br&gt;• Mean follow-up: 12 months</td>
<td>KT treated with empaglifozin (previous DM n = 4, PTDM n = 4)</td>
<td>All patients treated with empaglifozin&lt;br&gt;• Some patients taking concomitant antidiabetic drugs</td>
<td>• Slight initial worsening of renal function, but then stabilized (mean SCr from 88.5 to 99.5 mmol/L)&lt;br&gt;• Mean decrease of HbA1c of 0.85%&lt;br&gt;• Mean decrease of body weight of 2.4 kg&lt;br&gt;• Two patients developed UTI</td>
</tr>
<tr>
<td>Halden et al. [62]</td>
<td>• RCT, n = 49&lt;br&gt;• Follow-up: 24 weeks</td>
<td>KT recipients with diagnosis of PTDM</td>
<td>Empaglifozin (n = 22) versus placebo (n = 22)</td>
<td>• Statistically significant reduction of HbA1c compared with placebo: median −0.2% (IQR −0.6, −0.1) versus 0.1 (−0.1, 0.4); P = 0.025&lt;br&gt;• Median reduction of body weight of −2.5 kg (IQR −4.0, −0.05) compared with placebo group (P = 0.014)&lt;br&gt;• No significant differences in adverse events or eGFR</td>
</tr>
<tr>
<td>Mahling et al. [63]</td>
<td>• Case series, n = 10&lt;br&gt;• Median follow-up: 12 months</td>
<td>KT recipients receiving empaglifozin and eGFR &gt;45 mL/min/1.73 m²&lt;br&gt;• Includes PTDM and previous DM diagnosis</td>
<td>All patients received empaglifozin</td>
<td>• eGFR remained stable&lt;br&gt;• Slight decrease in the median of HbA1c of 0.2% (P &gt; 0.05)&lt;br&gt;• Median decrease of body weight −1.0 kg (IQR −1.9, −0.2 kg)</td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose; IQR, interquartile range; SPKT, simultaneous pancreas-kidney transplant

receive empaglifozin or placebo, with no differences in basal blood pressure levels or number of antihypertensive therapies. 24-h blood pressure measurements revealed no significant differences in systolic or diastolic blood pressure, or pulse [62]. These different effects compared with the non-KT diabetic population may be explained by different pathogenic mechanisms of CVD that depend not only on diabetes, but also on adverse effects directly related to immunosuppression.

iii. Kidney effects: improving renal function and outcomes of the graft. Renoprotective effects are related to SGLT2i-induced natriuresis by reducing proximal tubular sodium reabsorption and consequently increasing distal sodium delivery to the macula densa, activating tubulo-glomerular feedback, increasing afferent arteriolar tone, reducing renal perfusion, lowering glomerular pressure and reducing hyperfiltration [64]. The same mechanism may be present in KT recipients, but to our knowledge it is unknown and confirming studies are needed.

An increase of serum creatinine (Scr) and a decrease of eGFR are seen with the initiation of SGLT2i also in recipients with PTDM. This effect has been reported in two studies using empaglifozin: in a study including 14 recipients treated with this agent a reduction of eGFR from 55.6 to 47.5 mL/min/1.73 m² was shown at 4 weeks [60] and in another contemporary eight case-series report, similar increases in Scr were seen after 4 weeks (from 88.5 to 99.5 mmol/L). A stabilization of eGFR after this initial increase at 12 months has been confirmed in three studies [59, 61, 63]. A reduction of proteinuria has been reported only in one study, with a mean decrease of 0.6 g/day after 1 year [61]. In terms of adverse effects [14] data based on studies of general type 2 DM, the most frequent one is urinary tract infection.
Albuminuria Insulin resistance and (UTI). This is especially relevant in the KT population, who are more vulnerable because of chronic immunosuppression and genitourinary structural or functional abnormalities after the surgery. In this population, UTI can lead to a deterioration of renal function and, in the worst cases, graft loss. It has also been described that SGLT2i use in general DM recipients can be associated with genital mycotic infections and necrotizing fasciitis, which can be particularly harmful in immunosuppressed KT recipients. The risk of lower-limb amputation has been refuted in more recent studies [52–54, 56]. In studies focused on a few number of KT recipients, there were no more UTIs with SGLT2i use (incidences between 20% and 25%) [60, 61, 63], but due to the low number of patients included in these studies, these results have to be read with caution. Due to the absence of information in this KT population, it seems reasonable to avoid the use of these treatments in KT recipients with recurrent UTIs.

There are four EMA-approved DPP-4i (canagliflozin, dapagliflozin, empagliflozin and ertugliflozin). There are few known drug interactions with immunosuppressants and SGLT2i, with the exception of canagliflozin (Supplementary data, Table S3) [65, 66]. All SGLT2i are PGP substrates, but the only documented interaction is with canagliflozin use is a weak PGP inhibitor, which could result in increased calcineurin inhibitor and mycophenolate levels [30]. It is important to highlight that the only SGLT2i that can be given with eGFR ≤45 mL/min/1.73 m² is canagliflozin, with a dose of 100 mg orally daily (Supplementary data, Table S3) [14].

CONCLUSIONS

Seven recommendations for PTDM were proposed in the last meeting report of the American Diabetes Association, one of which was: ‘to adopt strategies for prevention and treatment beyond modification of immunosuppressive regimen’ [2]. To date, the only published study that evaluates a strategy to prevent PTDM showed that the use of insulin to treat hyperglycaemia in the immediate post-transplant period reduced the odds of persistent PTDM in the first year post-KT by 73% but with a higher number of hypoglycaemic episodes [67]. The treatment with insulin analogs in the early post-transplantation period is challenging since clinical conditions are changing rapidly (changes in renal function, nutrition management, GI motility disturbances or adjustment of immunosuppressive drugs). Thus, in these recipients, an intensive blood glucose monitoring is required with flexible and safe treatment algorithms.

Apart from the referred scarce published literature about the use of incretin agents and SGLT2i in PTDM, there are four ongoing studies that are presented in Supplementary data, Table S4. The studies showed their potential beneficial effect for the KT population in terms of control of glucose and cardiovascular risk factors. Nevertheless, whether the use of incretin agents and SGLT2i is associated with nephroprotection and with any effect on cardiovascular outcomes in solid organ transplant deserves further attention. Efficacy beyond glucose has not been conclusively demonstrated in the KT population (Figure 2). Moreover, it is necessary also to focus on evaluating particularly PK outcomes (Supplementary data, Table S5) and interaction with immunosuppression.

In summary, it is absolutely necessary to generate evidence in order to be able to safely use these new treatments in KT population and to establish a broader therapeutic strategy to improve blood glucose control and evaluate the role of these new agents in terms of cardiovascular and renal benefits, that would seem to be independent of blood glucose control, and in terms of their potential role as preventive strategies to avoid the appearance of PTDM. Subsequently, research needs might be focused on evaluating the effect of these agents on (i) kidney outcomes, (ii) cardiovascular outcomes and (iii) immunosuppression interaction, which could be addressed by RCTs comparing each of these molecules with the actual standard of care. Based on the effectiveness shown in the general type 2 DM population and the great incidence of cardiovascular outcomes in KT population, the sample size required would be feasible if a multicentric study is planned. Therefore, a call for clinical trials on PTDM treatment seems urgently needed.

SUPPLEMENTARY DATA

Supplementary data are available at ckj online.
CONFLICT OF INTEREST STATEMENT

Maria José Soler and Josep Maria Cruzado are Members of the CKJ Editorial Board.

REFERENCES


22. Capehorn MS, Catargir A-M, Furberg JK et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 2020; 46: 100–109


32. van Baar MJB, van der Aart AB, Hoogenberg K et al. The incretin pathway as a therapeutic target in diabetic kidney disease: A clinical focus on GLP-1 receptor agonists. Ther Adv Endocrinol Metab 2019; 10: 2042018819865398


Downloaded from https://academic.oup.com/ckj/article/15/1/5/6319019 by guest on 27 January 2022
Management of PTDM | 13